CM Wealth Advisors LLC Buys New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• CM Wealth Advisors initiated a Thermo Fisher Scientific position of 1,693 shares valued at approximately $850,000. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly earnings of $6.03 per share, beating estimates by $0.32, while revenue rose 10.5% year over year to $11.99 billion. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $619.41. Meanwhile, company insiders sold approximately $37.7 million of stock over the past three months.

CM Wealth Advisors LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,693 shares of the medical research company's stock, valued at approximately $850,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock worth $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP boosted its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. State Street Corp raised its position in shares of Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after buying an additional 229,630 shares during the period. Finally, Capital World Investors boosted its holdings in Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock valued at $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $628.24 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The firm has a market cap of $232.29 billion, a P/E ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85. The stock has a fifty day moving average price of $539.33 and a two-hundred day moving average price of $508.86. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the prior year, the firm posted $4.28 earnings per share. The company's revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 63,493 shares of company stock worth $37,657,681. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. KeyCorp restated an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating for the company in a report on Friday, May 8th. Piper Sandler increased their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a research note on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source